Cytokines News and Research

Latest Cytokines News and Research

New understanding of CD44 receptor's role in immune cell survival

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.

29 Jan 2010

Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

Anacor Pharmaceuticals announced today that it will present a poster and oral presentation on a novel systemic anti-inflammatory candidate, AN6415, at the upcoming 8th Cytokines and Inflammation Conference, taking place January 28-29, 2010 in La Jolla, California.

28 Jan 2010

Elevated cytokine levels are early indicator of rheumatoid arthritis

Researchers from University Hospital in Umea, Sweden, have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis (RA) disease onset. These findings confirm those of earlier studies which suggest that the risk of developing RA can be predicted and disease progression may be prevented.

28 Jan 2010

HTDS evaluates business proposal ahead of dividend distribution

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) subsidiary Slavica Bio Chem recently announced entry into the stem cell bank development. An unsolicited business proposal is currently being evaluated by the company from an obstetrician type medical company. This company is engaged in a treatment for pre-term labor and induction of labor. These symptoms affect millions of people worldwide.

23 Jan 2010

Medical student receives 2009 Lucien Rubenstein Award

The American Brain Tumor Association has announced that Alexander Ksendzovsky, a third-year medical student at the Chicago Medical School of Rosalind Franklin University in North Chicago, is the 2009 Lucien Rubenstein Award recipient.

21 Jan 2010

CytoDyn commences enrollment in Cytolin clinical trial

Following approval of the Institutional Review Board, CytoDyn, Inc. has discharged its duty to register a clinical trial of Cytolin®, the Company’s lead product, with the government’s website at www.clinicaltrials.gov, ID NCT01048372. The public has online access to this federal database, which describes the key elements of clinical trials and their status.

19 Jan 2010

Prescription drugs prove effective in managing moderate to severe psoriasis

Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

NeuroScience launches NEI Guided Nutrition Program

NeuroScience, Inc. has launched a comprehensive and customizable dietary program based on patients' food sensitivity test results. The NEI Guided Nutrition Program(TM) is the first offering through NeuroScience, Inc.'s new NEI Nutrition(TM) division.

12 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

Immune cells causes inflammation in thyroid-associated ophthalmopathy

A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.

9 Jan 2010

Fibrocytes associated with Graves' disease

9 Jan 2010

Genentech's ACTEMRA approved to treat RA

Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

8 Jan 2010

LSUHSC receives $2.1 million grant for pneumonia research

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to further his work on a discovery that plays a critical role in the body's defense against pneumonia.

8 Jan 2010

$HIV-infected postmenopausal women face higher risk for accelerated bone loss and fracture$

HIV-infected postmenopausal women face higher risk for accelerated bone loss and fracture

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), postmenopausal HIV-infected women have a high prevalence of low bone mineral density and high bone turnover placing them at high risk for future bone fractures.

5 Jan 2010

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Gene's role in immune system may suggest new treatments for childhood asthma

Pediatric researchers have identified a novel gene involved in childhood asthma, in one of the largest gene studies to date of the common respiratory disease. Because the gene, called DENND1B, affects cells and signaling molecules thought to be instrumental in the immune system overreaction that occurs in asthma, the discovery may have singled out an important target for new treatments.

23 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.

21 Dec 2009